Tafenoquine Sustains Malaria Transmission Blocking Longer
Preclinical mouse studies compare how primaquine and tafenoquine block malaria parasite transmission over time.
Updated on Nov. 10, 2026 in Life Sciences

Researchers compared the transmission-blocking activity of primaquine and tafenoquine in in vivo preclinical models. Primaquine showed stronger early activity 24 hours after treatment, while tafenoquine retained greater activity at later time points.
Why it matters
Primaquine is given as a single low dose alongside antimalarial treatment to reduce malaria transmission, so the timing of its effect shapes how it is used. The distinct temporal profiles suggest the two drugs may suit different points in the treatment window.
The comparison used Plasmodium berghei-infected mice, with an equimolar dose of tafenoquine tested in a mouse-to-mosquito-to-mouse transmission model. In humanized mice, both drugs reduced gametocyte abundance in a dose-dependent manner, but whether these animal results carry over to human transmission is not addressed.
The details
Tafenoquine shows sustained exposure for several days, while parent primaquine declines more rapidly. Similar temporal differences appeared when each drug was combined with the schizonticide sulphadiazine.
Timeline
Primaquine produced stronger transmission-blocking activity at 24 hours after treatment, per the study's time points.
The Big Picture
Primaquine and tafenoquine have distinct temporal transmission-blocking profiles in vivo, with primaquine acting faster and tafenoquine acting over a longer window. This comparison refines how the two existing antimalarial drugs are understood as tools for reducing transmission.
For people in malaria-endemic regions, these findings bear on how single-dose transmission-blocking treatments are timed alongside antimalarial therapy. The practical impact depends on whether the animal results hold up in human studies.
The takeaway
Primaquine acts quickly while tafenoquine persists longer, so the two drugs may complement each other depending on when transmission needs to be blocked. Readers should treat these as preclinical results that still require confirmation in human studies.
Further reading
For related context, explore more coverage in Life Sciences.
Source note: This article includes information reported by Nature.







